


PRODUCT INFORMATION



Amuvatinib

Item No. 21461

CAS Registry No.: 850879-09-3
Formal Name: N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide
Synonyms: HPK56, MP470
MF: C₂₃H₂₁N₅O₃S
FW: 447.5
Purity: ≥98%
UV/Vis.: λ_{max}: 244, 290, 315 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Amuvatinib is supplied as a crystalline solid. A stock solution may be made by dissolving the amuvatinib in the solvent of choice, which should be purged with an inert gas. Amuvatinib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of amuvatinib in these solvents is approximately 10 and 20 mg/ml, respectively.

Amuvatinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, amuvatinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Amuvatinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Amuvatinib is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor α (PDGFRα), and c-Met (IC₅₀s = 10, 40, and 81 nM, respectively).¹ It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib (Item No. 10483).¹ Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.²⁻⁴

References

1. Qi, W., Cooke, L.S., Stejskal, A., *et al.* MP470, a novel receptor tyrosine kinase inhibitor, in combination with erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. *BMC Cancer* **9**(142), 1-12 (2009).
2. Padda, S., Neal, J.W., and Wakelee, H.A. MET inhibitors in combination with other therapies in non-small cell lung cancer. *Transl. Lung Cancer Res.* **1**(4), 238-253 (2012).
3. Welsh, J.W., Mahadevan, D., Ellsworth, R., *et al.* The c-met-receptortyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. *Radiat. Oncol.* **4**(69) (2009).
4. Zhao, H.L., Luoto, K.R., Meng, A.X., *et al.* The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. *Radiother. Oncol.* **101**(1), 59-65 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM